Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stake Boosted by Perceptive Advisors LLC

Perceptive Advisors LLC boosted its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 62.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,716,407 shares of the biopharmaceutical company's stock after acquiring an additional 661,052 shares during the period. Intra-Cellular Therapies accounts for approximately 2.8% of Perceptive Advisors LLC's investment portfolio, making the stock its 9th biggest position. Perceptive Advisors LLC owned about 1.63% of Intra-Cellular Therapies worth $117,557,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of ITCI. Oak Ridge Investments LLC purchased a new stake in shares of Intra-Cellular Therapies in the second quarter valued at approximately $811,000. SG Americas Securities LLC increased its stake in shares of Intra-Cellular Therapies by 962.7% in the 2nd quarter. SG Americas Securities LLC now owns 48,778 shares of the biopharmaceutical company's stock worth $3,341,000 after acquiring an additional 44,188 shares during the last quarter. Schroder Investment Management Group boosted its position in shares of Intra-Cellular Therapies by 36.7% during the 4th quarter. Schroder Investment Management Group now owns 779,823 shares of the biopharmaceutical company's stock valued at $55,851,000 after acquiring an additional 209,331 shares during the last quarter. Clearbridge Investments LLC boosted its position in shares of Intra-Cellular Therapies by 12.3% during the 1st quarter. Clearbridge Investments LLC now owns 1,744,551 shares of the biopharmaceutical company's stock valued at $120,723,000 after acquiring an additional 191,416 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in shares of Intra-Cellular Therapies in the first quarter valued at about $18,379,000. Institutional investors and hedge funds own 92.33% of the company's stock.

Intra-Cellular Therapies Stock Up 0.1 %

Shares of ITCI opened at $73.30 on Monday. The company has a market cap of $7.74 billion, a P/E ratio of -63.19 and a beta of 1.00. Intra-Cellular Therapies, Inc. has a fifty-two week low of $45.50 and a fifty-two week high of $84.89. The firm's 50 day moving average price is $75.44 and its 200 day moving average price is $71.77.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.03. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The business had revenue of $161.40 million for the quarter, compared to analysts' expectations of $157.74 million. During the same period last year, the firm earned ($0.45) earnings per share. The company's revenue for the quarter was up 45.7% compared to the same quarter last year. Research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.59 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on ITCI. Needham & Company LLC reiterated a "buy" rating and issued a $100.00 target price on shares of Intra-Cellular Therapies in a report on Wednesday, August 7th. UBS Group decreased their price objective on Intra-Cellular Therapies from $83.00 to $79.00 and set a "neutral" rating on the stock in a report on Thursday, August 8th. JPMorgan Chase & Co. raised their target price on Intra-Cellular Therapies from $79.00 to $81.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 21st. Royal Bank of Canada decreased their price target on Intra-Cellular Therapies from $107.00 to $106.00 and set an "outperform" rating on the stock in a research note on Thursday, August 8th. Finally, Canaccord Genuity Group raised their price objective on Intra-Cellular Therapies from $107.00 to $113.00 and gave the stock a "buy" rating in a research report on Thursday, June 20th. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $96.58.

Insider Activity

In related news, CEO Sharon Mates sold 53,013 shares of the company's stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $80,970,388.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Sharon Mates sold 53,013 shares of the business's stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $80,970,388.85. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Mark Neumann sold 18,714 shares of the firm's stock in a transaction on Friday, August 16th. The shares were sold at an average price of $75.08, for a total value of $1,405,047.12. Following the completion of the sale, the executive vice president now owns 29,700 shares in the company, valued at $2,229,876. The disclosure for this sale can be found here. In the last quarter, insiders sold 175,316 shares of company stock worth $13,037,345. 3.40% of the stock is currently owned by company insiders.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.